GGrantIndex
← Leaderboards

Lisa Mosconi

University Of Arizona

Google Scholar ↗PubMed ↗ORCID ↗
$10,441,680
Attributed
$17,725,337
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.1M · FY2008–25
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$17,725,337 · 7

By mechanism

R01$12,531,357 · 3
P01$4,756,626 · 2
R21$427,219 · 1
P41$10,135 · 1

Top collaborators

Most similar at University Of Arizona

Same institution · by research overlap

Others in their field

Top investigators on “Alzheimer&Apos”

Research focus

Alzheimer&AposS DiseaseMetabolicBrainMagnetic Resonance ImagingImageS Disease RiskMitochondriaGlucose MetabolismPeripheralMiddle AgeWomanPreventPre-ClinicalFemaleBiological MarkersLifeBrain ImagingBioenergeticsApolipoprotein E-4BiologyAging BrainMetabolomicsMission

Grant awards (21)

Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows$994,350
P01 · FY2025 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,327,969
R01 · FY2024 · AG
Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows$766,713
P01 · FY2024 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$1,544,481
R01 · FY2023 · AG
Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows$821,928
P01 · FY2023 · AG · contact PI
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial$2,121,223
R01 · FY2022 · AG
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,130,295
R01 · FY2022 · AG
Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows$832,970
P01 · FY2022 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,107,464
R01 · FY2021 · AG
Project 4: Longitudinal Brain Imaging for Alzheimer's Biomarkers across Peri to Post Menopausal Transition: Therapeutic Targets and Windows$857,388
P01 · FY2021 · AG · contact PI
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,134,417
R01 · FY2020 · AG
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,141,341
R01 · FY2019 · AG
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$300,580
R01 · FY2019 · AG
Sex Differences in the Molecular Determinants of Alzheimer's Disease Risk: Prodromal Endophenotype$1,192,861
R01 · FY2018 · AG
Perimenopause in APOE4 Brain: Clinical Outcomes and Global Impact$483,277
P01 · FY2018 · AG · contact PI
History of Alzheimer predisposes children to amyloid beta-related hypometabolism$531,465
R01 · FY2014 · AG · contact PI
History of Alzheimer predisposes children to amyloid beta-related hypometabolism$478,649
R01 · FY2013 · AG · contact PI
History of Alzheimer predisposes children to amyloid beta-related hypometabolism$520,612
R01 · FY2012 · AG · contact PI
PRECLINICAL DETECTION OF AD (ABBREAVIATE AS FAMHXAD)$10,135
P41 · FY2011 · RR · contact PI
Family History of Alzheimer's, Hypometabolism and Oxidative Stress$191,483
R21 · FY2009 · AG · contact PI
Family History of Alzheimer's, Hypometabolism and Oxidative Stress$235,736
R21 · FY2008 · AG · contact PI